The global pharmaceutical industry experienced a 30% drop in company filings mentions of microbiome in Q1 2023 compared with the previous quarter, with the highest share accounted for by Novozymes with 9% year-on-year decrease, according to GlobalData’s analysis of over 50 pharmaceutical company filings. GlobalData’s Microbiome-Targeting Therapeutics in Infectious Diseases – Thematic Research report provides information on market classification by therapy and technologies, regulatory and market access details for live biotherapeutic products (LBP) in the US and 5EU, and product & company profiles. It helps identify which indications are the mo Buy the report here.
Notably, microbiome was one of the most frequently referenced themes in Q1 2023, ranking highest in terms of mentions, ahead of autonomous vehicles and regtech, according to GlobalData.
Of the top leading companies in the pharmaceutical industry, Novozymes had the greatest increase in references for microbiome in Q1 2023, compared with the previous quarter. GlobalData identified 29 microbiome-related sentences in the company's filings - 0.8% of all sentences - and an increase of 100% in Q1 2023 compared with Q1 2022. Bayer’s mentions of microbiome rose by 100% to 1 and Sanofi’s by 100% to 1.
GlobalData’s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for microbiome in Q1 2023 was 70.
For further understanding of GlobalData's Microbiome-Targeting Therapeutics in Infectious Diseases – Thematic Research buy the report here.